Michael Happich

Michael Happich

UNVERIFIED PROFILE

Are you Michael Happich?   Register this Author

Register author
Michael Happich

Michael Happich

Publications by authors named "Michael Happich"

Are you Michael Happich?   Register this Author

41Publications

565Reads

28Profile Views

Do You Want to Hear the Bad News? The Value of Diagnostic Tests for Alzheimer's Disease.

Value Health 2016 Jan 12;19(1):66-74. Epub 2016 Jan 12.

Eli Lilly and Company Limited, Windlesham, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2015.10.011DOI Listing
January 2016

Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.

Alzheimers Dement 2015 Aug 4;11(8):933-45. Epub 2015 Apr 4.

Parc Santari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jalz.2015.02.005DOI Listing
August 2015

Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.

J Ment Health Policy Econ 2015 Jun;18(2):63-73

3715 Haven Avenue, Suite 100, Menlo Park, CA 94025, USA,

View Article

Download full-text PDF

Source
June 2015

Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.

Prim Care Companion CNS Disord 2014 2;16(5). Epub 2014 Oct 2.

Eli Lilly-Brazil, Brazil Medical Affairs, Sao Paulo, Brazil (Dr Barros); Eli Lilly and Company, Global Statistical Sciences, Bad Homburg, Germany (Drs Schacht, Happich, and Ms Berggren); Lilly UK, Lilly Research Centre, Windlesham, Surrey, United Kingdom (Ms Televantou); Lilly USA, LLC, Indianapolis, Indiana (Dr Walker); and Eli Lilly de México, Mexico City, Mexico (Dr Dueñas).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/PCC.14m01661DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321013PMC
February 2015

Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study.

Clin J Pain 2014 Oct;30(10):875-85

*Medical Department, Health Technology Appraisal Group †Regional Medical Affairs ‡Global Statistical Sciences, Lilly Deutschland GmbH, Bad Homburg §Klinik und Poliklinik für Neurologie, Johannes Gutenberg Universität, Mainz ∥Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research, Heinrich Heine University ¶Department of Endocrinology and Diabetology, University Hospital, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/AJP.0000000000000057DOI Listing
October 2014

Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review.

Appl Health Econ Health Policy 2013 Dec;11(6):593-618

Medical Decision Modeling Inc., 8909 Purdue Road, Suite #550, Indianapolis, IN, 46268, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-013-0061-xDOI Listing
December 2013

Authors' reply to Liedgens and Henske: "cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective".

Appl Health Econ Health Policy 2013 Oct;11(5):555-7

Medical Decison Modeling, Indianapolis, IN, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-013-0049-6DOI Listing
October 2013

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

Appl Health Econ Health Policy 2013 Jun;11(3):219-36

Medical Decision Modeling Inc., 8909 Purdue Road, Suite #550, Indianapolis, IN 46268, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40258-013-0031-3
Publisher Site
http://dx.doi.org/10.1007/s40258-013-0031-3DOI Listing
June 2013

Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.

Spine (Phila Pa 1976) 2013 May;38(11):936-46

Medical Decision Modeling Inc., Indianapolis, IN 46268, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BRS.0b013e31828264f9DOI Listing
May 2013

The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.

Value Health 2013 Mar-Apr;16(2):334-44

Medical Decision Modeling Inc., Indianapolis, IN 46268, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2012.12.006DOI Listing
May 2013

Costs associated with treatment of chronic low back pain: an analysis of the UK General Practice Research Database.

Spine (Phila Pa 1976) 2013 Jan;38(1):75-82

Personal Social Services Research Unit, London School of Economics and Political Science, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BRS.0b013e318276450fDOI Listing
January 2013

Healthcare utilization among patients with depression before and after initiating duloxetine in the United Kingdom.

J Med Econ 2012 20;15(4):672-80. Epub 2012 Mar 20.

Thomson Reuters, Outcomes Research, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3111/13696998.2012.672941DOI Listing
October 2012

Depression treatment with duloxetine and reduction of inability to work.

Depress Res Treat 2012 2;2012:264854. Epub 2012 Aug 2.

Medical Department, Lilly Deutschland GmbH, 61352 Bad Homburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/264854DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419398PMC
August 2012

Health state valuation methods and reference points: the case of tinnitus.

Value Health 2009 Jan-Feb;12(1):88-95

Helmholtz Zentrum München-German Research Center for Environmental Health, Institute of Health Economics and Health Care Management (IGM), Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1524-4733.2008.00397.xDOI Listing
November 2009

Diabetic retinopathy and health-related quality of life.

Graefes Arch Clin Exp Ophthalmol 2009 Feb 17;247(2):267-72. Epub 2008 Oct 17.

University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00417-008-0960-yDOI Listing
February 2009

The effect of insulin lispro on glycemic control in a large patient cohort.

Diabetes Technol Ther 2009 Jan;11(1):51-6

Department of Medicine, Uddevalla Hospital, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/dia.2007.0297DOI Listing
January 2009

Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross sectional study.

BMC Health Serv Res 2008 Nov 5;8:226. Epub 2008 Nov 5.

Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Institute of Epidemiology, Neuherberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1472-6963-8-226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605747PMC
November 2008

The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002--results from the Diabetic Microvascular Complications (DIMICO) study.

Diabetes Res Clin Pract 2008 Aug 7;81(2):223-30. Epub 2008 Jul 7.

Lilly Deutschland GmbH, Saalburgerstr. 153, 61350 Bad Homburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.diabres.2008.03.019DOI Listing
August 2008

The economic burden of diabetic retinopathy in Germany in 2002.

Graefes Arch Clin Exp Ophthalmol 2008 Jan 4;246(1):151-9. Epub 2007 Apr 4.

Eli Lilly and Company, Bad Homburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00417-007-0573-xDOI Listing
January 2008

Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.

Eur Arch Psychiatry Clin Neurosci 2007 Sep 1;257(6):330-6. Epub 2007 Apr 1.

Alzheimer Memorial Center and Geriatric Psychiatry Branch, Dementia and Neuroimaging Section, Department of Psychiatry, Ludwig-Maximilian University, Nussbaumstr.7, Munich, 80336, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00406-007-0727-1DOI Listing
September 2007

Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set.

Eur J Health Econ 2007 Mar;8(1):31-9

Institute of Health Economics, GSF National Research Center for Environment and Health, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10198-006-0004-7DOI Listing
March 2007

Valuing the health state 'tinnitus': differences between patients and the general public.

Hear Res 2005 Sep;207(1-2):50-8

GSF-National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, P.O. Box 1129, 85758 Neuherberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.heares.2005.04.002DOI Listing
September 2005

[Cost-effectiveness of galantamine in a german context].

Psychiatr Prax 2005 Apr;32(3):142-50

GSF-Forschungszentrum für Umwelt und Gesundheit, Institut für Gesundheitsökonomie und Management im Gesundheitswesen, Neuherberg.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2004-834709DOI Listing
April 2005

An exponential representation of health state utility.

Eur J Health Econ 2003 Nov;4(4):292-4

National Research Center for Environment and Health, Neuherberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10198-003-0186-1DOI Listing
November 2003